Theranostic Nanoplatform with Hydrogen Sulfide Activatable NIR Responsiveness for Imaging-Guided On-Demand Drug Release

Angew Chem Int Ed Engl. 2019 Nov 18;58(47):16826-16830. doi: 10.1002/anie.201909883. Epub 2019 Oct 14.

Abstract

NIR light responsive nanoplatforms hold great promise for on-demand drug release in precision cancer medicine. However, currently available systems utilize "always-on" photothermal transducers that lack target specificity, and thus inaccurately differentiate tumors from normal tissues. Developed here is a theranostic nanoplatform featuring H2 S-mediated in situ production of NIR photothermal agents for imaging-guided and photocontrolled drug release. The system targets H2 S-rich cancers. This nanoplatform shows H2 S-activatable NIR-II emission and NIR light controllable release of the drug Camptothecin-11. Upon administering the system to HCT116 tumor-bearing mice, the tumor is greatly suppressed with minimal side effects, arising from the synergy of the cancer-specific and NIR light activated therapy. This theranostic nanoplatform thus sheds light on precision medicine with guidance through NIR-II imaging.

Keywords: cancer; drug delivery; fluorescence; nanostructures; theranostics.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Apoptosis
  • Cell Proliferation
  • Colonic Neoplasms / diagnostic imaging
  • Colonic Neoplasms / pathology
  • Colonic Neoplasms / therapy*
  • Drug Liberation*
  • Humans
  • Hydrogen Sulfide / chemistry*
  • Irinotecan / pharmacology*
  • Mice
  • Nanoparticles / administration & dosage*
  • Nanoparticles / chemistry
  • Phototherapy*
  • Theranostic Nanomedicine*
  • Topoisomerase I Inhibitors / pharmacology
  • Tumor Cells, Cultured
  • Xenograft Model Antitumor Assays

Substances

  • Topoisomerase I Inhibitors
  • Irinotecan
  • Hydrogen Sulfide